This site is intended for health professionals only

MHRA issues safety information on medicines for healthcare professionals

teaser

The MHRA has compiled a list of letters sent to UK healthcareprofessionals in April 2007, to deliver new safety information andadvice. Topics include:

• Mabthera® (rituximab): reports ofprogressive multifocal leukoencephalopathy in unapproved indications ofsystemic lupus erythematosus and vasculitis.

• Pioglitazone-containing products: risk of fractures in women on long-term treatment.

• Cabaser® (cabergoline): pathological gambling and increased libido are potential class effects of dopamine agonists.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

• Desmopressin: removal of primary nocturnal enuresis indication.

• Ketek® (telithromycin): important information about restricted indications, contraindications and safety measures.

•Ventolin® (salbutamol): new prescribing advice for obstetric use inmanagement of preterm labour and use in respiratory disease.

New Electronic Library for Medicines 2/5/2007

 






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x